
Sign up to save your podcasts
Or


Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center, Singapore (with a special interest in all aspects of triple-negative breast cancer), shared the key areas of progress covered by the meeting.
HPV vaccination for girls and boys in the United States has led to a real-world reduction of oral head and neck cancers in men, as well as the already documented prevention of cervical cancers in women, even though uptake of the vaccine in the U.S. has been suboptimal. This is according to findings from a retrospective analysis of HPV-associated cancer incidence, reported at the 2024 ASCO Annual Meeting.
At the Chicago meeting, OncTimesTalk reporter Peter Goodwin met up with the lead author of the research, Jefferson DeKloe, BSc, from the Department of Otolaryngology at Thomas Jefferson University in Philadelphia.
Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden.
Furthermore, the study found a higher than previously reported negative interaction of PPI comedication on crystalline dasatinib bioavailability that may compromise clinical efficacy and risk CML disease progression.
The latest findings from the study were reported in a poster session at the 2024 ASCO Annual Meeting where Oncology Times reporter Peter Goodwin met up with Olof Harlin, PhD, of Xspray Pharma, based in Solna, near Stockholm, Sweden.
Patients who had immune-related adverse events had better responses and lived longer than those who didn't. This was a real-world observational study of patients with recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint inhibitor monotherapy, reported at the 2024 ASCO Annual Meeting.
OncTimesTalk reporter Peter Goodwin caught up with the lead study author Chiara Gottardi, MD, who specializes in head and neck cancer in the Department of Surgery, Oncology, and Gastroenterology in the Istituto Oncologico Veneto at the University of Padova in Italy.
A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia.
Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of London were reported at a poster session of the 2024 ASCO Annual Meeting.
Oncology Times correspondent Peter Goodwin attended the session and talked with the second author of the study, Weronika E. Borek PhD, a Bioinformatics Technical Lead at Kinomica Limited in London.
When the mucin-1 (MUC-1) vaccine tecemotide was added to standard-of-care neoadjuvant systemic therapy, investigators in Austria found improved long-term outcomes in women with early breast cancer. Individuals vaccinated with tecemotide had markedly longer distant recurrence-free and overall survival. This was in the randomized prospective ABCSG-34 trial presented at the 2024 ASCO Annual Meeting.
Oncology Times reporter Peter Goodwin met up in Chicago with the lead study author, Christian F. Singer MD, a gynecologist specializing in breast cancer at the Department of Obstetrics and Gynecology and the Comprehensive Cancer Center of the Medical University of Vienna, in Vienna, Austria.
Not only can palliative care be delivered effectively by telehealth to patients with advanced non-small cell lung cancer, it's also as effective as face-to-face delivery by specialist clinicians, according to a study reported at the 2024 ASCO Annual Meeting. In addition, telehealth turned out to be more popular.
For the Oncology Times podcast, OncTimesTalk, correspondent Peter Goodwin spoke with Joseph A. Greer, PhD, lead author of the study and Co-Director of the Cancer Outcomes Research and Education Program at Massachusetts General Hospital and Harvard Medical School.
The CARACO prospective, multi-institutional, Phase III trial, among patients with newly diagnosed advanced epithelial ovarian cancer, found that lymphadenectomy should be omitted in patients with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery. This finding from the University of Nantes was reported at the 2024 ASCO Annual Meeting. The researchers noted this surgical de-escalation allows significant reduction of serious post-operative morbidity
After the session, Oncology Times correspondent Peter Goodwin learned about more study details from Jean-Marc Classe, MD, PhD, Professor of Surgery in the Department of Surgical Oncology in the Institut de Cancérologie de l'Ouest and Nantes University in Western France.
A combination of two checkpoint inhibitors used as neoadjuvant therapy for macroscopic, resectable Stage III melanoma brought a highly statistically significant improvement over the standard of care: surgery followed by checkpoint inhibition (therapeutic lymph node dissection followed by adjuvant therapy with nivolumab, pembrolizumab or, in BRAFmut melanoma, dabrafenib + trametinib). This research was reported from the ASCO 2024 Annual Meeting and highlighted the NADINA trial from the Netherlands.
After his session at ASCO, the lead author of NADINA, Christian U. Blank, MD, PhD, from the Netherlands Cancer Institute and Antoni van Leeuwenhook Hospital, Amsterdam, the Netherlands, met up with Oncology Times reporter Peter Goodwin to discuss the findings.
Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting.
First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital, the South Australian Health and Medical Research Institute, and the University of Adelaide in Australia, reported higher efficacy in terms of major molecular responses and lower toxicity with asciminib. After his talk in Chicago, he met up with Oncology Times reporter, Peter Goodwin.
From the publisher's feed